HJ-037

HJ-037: sourced facts only. name: "HJ-037 is an orally available, potent, and highly selective covalent KRASG12C inhibitor, which showed significantly superior inhibitory activities against NCI-H358 and Mia PaCa-2 cells to current marketed KRASG12C inhibitors, and favorable safety profile was observed in pre-clinical study, providing a good safety foundation for its combination with PD-1 inhibitor." [DOI:10.1158/1538-7445.am2025-3038]; target: "HJ-037 is an orally available, potent, and highly selective covalent KRASG12C inhibitor, which showed significantly superior inhibitory activities against NCI-H358 and Mia PaCa-2 cells to current marketed KRASG12C inhibitors, and favorable safety profile was observed in pre-clinical study, providing a good safety foundation for its combination with PD-1 inhibitor." [DOI:10.1158/1538-7445.am2025-3038]; developer: "Chengdu Huajian Science Co., Ltd., Chengdu, China." [DOI:10.1158/1538-7445.am2025-3038]; stage: "In a Colon Cancer CT26-mKRASG12C cell line subcutaneous syngeneic model, animals treated with HJ-037 plus anti-PD-1 antibody showed complete tumor regression without recurrence." [DOI:10.1158/1538-7445.am2025-3038]